2. Johnson & Johnson - Top 15 R&D Budgets

Who: Johnson & Johnson

Based: United States

2006 Pipeline Budget: $7.9 billion (€5.40B)

2007 Pipeline News: This year, J&J’s pipeline seemed to take a back seat to the controversy surrounding anemia drug safety. But analysts weren’t too busy speculating over the drugmaker’s anemia drug woes to take note of J&J’s anticipated slowdown in growth. J&J has several late-stage drugs that hold the key to the company’s future. These include telaprevir, two HIV drugs, golimumab (which it's developing with Schering-Plough) and rivaroxaban. Company officials anticipate 18 to 21 new drug filings or approvals over the next three years; five of those are expected by the end of 2007.

Pending Approval:

> Concerta - Adult ADHD
> Remicade - Pediatric Ulcerative Colitis, UC colectomy avoidance
> Ceftobiprole - Complicated Skin and Skin Structure Infections
> Doribax - Nosocomial Pneumonia
> TMC125 - NNRTI HIV/AIDS treatment-experienced patients

Phase III:

> Invega (paliperidone ER OROS) - Bipolar mania
> Paliperidone palmitate IM long acting injectable - Schizophrenia
> Risperdal Consta - Bipolar maintenance, Deltoid injection
> Carisbamate - Epilepsy
> Topomax - Pediatric exclusivity
> CNTO 1275 (ustekinumab) - Psoriasis
> CNTO 148 (golimumab) - Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis Rheumatoid Arthritis
> Procrit - Chronic Renal Function
> Ceftobiprole - Nosocomial Pneumonia, Hospitalized community acquired pneumonia
> Doxil - Breast Cancer
> Velcade - Non-Hodgkin's Lymphoma, Multiple Myeloma 1st line
> Yondelis - Relapsed Ovarian Cancer
> Dacogen - Injection Myelodysplastic Syndromes
> Prezista - Naïve & early experienced patients
> Tapentadol - Moderate to severe acute pain (IR formulation), moderate to severe chronic pain (ER formulation)
> Rivaroxaban VTE Prophylaxis, knee replacement surgery, stroke prevention in atrial fibrillation, VTE treatment

Full Pipeline Site: Link

2. Johnson & Johnson - Top 15 R&D Budgets

Suggested Articles

Last month, rumors out of Bloomberg whispered that Gilead, more known for its COVID-19 work these days, was gearing up for a major stake in Arcus.

The NGOs think Big Pharma controls the agenda of the IMI, leading it to prioritize areas that are profitable for drugmakers over public health needs.

Scientists at McMaster University and the University of Toronto have formed Empirica Therapeutics to bring a CAR-T for glioblastoma into the clinic.